Mounjaro Kwikpen 2.5mg (Tirzepatide) – Switzerland
Mounjaro KwikPen 2.5 mg – Prescription Information
Mounjaro KwikPen 2.5 mg contains the active ingredient tirzepatide and is a prescription-only medicine authorised in Switzerland. It is supplied as an injectable solution in a pre-filled pen and is used under the supervision of an appropriate healthcare professional.
In Switzerland, Mounjaro is authorised for adults with inadequately controlled type 2 diabetes mellitus, alongside diet and exercise. Swissmedic has also authorised an indication for chronic weight management in eligible adults, in combination with a reduced-calorie diet and increased physical activity. (Swissmedic)
The 2.5 mg strength is used as the usual initial dose. Treatment and any subsequent dose adjustment should be determined by the prescribing healthcare professional according to the authorised product information and the individual patient’s circumstances. (Swissmedic)
What Is Mounjaro Kwikpen 2.5mg?
Mounjaro contains tirzepatide, a medicine that acts on both GIP and GLP-1 receptors. These hormonal pathways are involved in blood-glucose regulation and appetite regulation. Mounjaro Kwikpen 2.5mg
For eligible patients, tirzepatide can support improved blood-glucose control in type 2 diabetes and can contribute to weight reduction when used as part of an appropriate treatment programme. Swissmedic reports that Mounjaro’s weight-management indication is intended for eligible adults alongside a calorie-reduced diet and increased physical activity. Mounjaro Kwikpen 2.5mg near me
Mounjaro Kwikpen 2.5mg in Switzerland
Swissmedic lists Mounjaro as an injectable solution supplied in a pre-filled pen in several strengths, including 2.5 mg/0.5 ml, 5 mg/0.5 ml, 7.5 mg/0.5 ml, 10 mg/0.5 ml, 12.5 mg/0.5 ml and 15 mg/0.5 ml. Mounjaro Kwikpen 2.5mg (Swissmedic)
Mounjaro Kwikpen 2.5mg is a prescription medicine, meaning it should only be obtained and used in accordance with Swiss pharmaceutical requirements and the advice of a qualified healthcare professional. Mounjaro Kwikpen 2.5mg
How Is Mounjaro Kwikpen 2.5mg Used?
The authorised starting regimen is Mounjaro Kwikpen 2.5mg once weekly. According to Swissmedic’s published information, the dose may subsequently be increased in 2.5 mg increments at appropriate intervals, under medical supervision, when clinically indicated. The maximum authorised dose is 15 mg once weekly. (Swissmedic)
Mounjaro Kwikpen 2.5mg is administered by subcutaneous injection. The authorised information identifies the abdomen, thigh or upper arm as injection areas. Patients should follow the instructions supplied with their medicine and those provided by their healthcare professional. (Swissmedic)
Do not change the dose, injection schedule or administration technique without consulting your prescriber.
Mounjaro Kwikpen 2.5mg and Weight Management
Mounjaro received an indication extension in Switzerland in July 2024 for chronic weight management in eligible adults. Swissmedic states that treatment is intended for adults with an initial BMI of 30 kg/m² or greater, or 27 kg/m² to below 30 kg/m² when at least one weight-related health condition is present. Examples include hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes and type 2 diabetes. (Swissmedic)
Mounjaro should therefore not be presented as a general-purpose slimming product. Suitability for treatment must be assessed by a qualified healthcare professional.
Important Safety Information
Mounjaro is not suitable for everyone. Swissmedic states that it must not be used in people with hypersensitivity to tirzepatide or any of the product’s excipients. (Swissmedic)
The most commonly reported adverse effects include gastrointestinal symptoms, such as nausea, diarrhoea, constipation and vomiting. Other warnings, precautions, contraindications, interactions and potential adverse effects are detailed in the authorised professional and patient information. (Swissmedic)
Patients using insulin or sulfonylureas may have an increased risk of hypoglycaemia, and appropriate treatment adjustments may be required by the prescribing healthcare professional. (Swissmedic)
Swissmedic issued a healthcare professional communication on 27 July 2026 specifically concerning the correct use of Mounjaro KwikPen and emphasized the importance of following the official instructions for use and patient information. (Swissmedic)
Who Should Consider Mounjaro?
Mounjaro should only be considered following an appropriate medical assessment. A healthcare professional can determine whether tirzepatide is suitable based on factors including:
- Medical history
- Current medications
- Type 2 diabetes status
- Weight-management requirements
- BMI and associated health conditions
- Previous treatment
- Potential contraindications
- Individual treatment goals
A prescription does not replace ongoing medical supervision.
Product Information
Product: Mounjaro KwikPen
Active ingredient: Tirzepatide
Strength: 2.5 mg
Presentation: Injectable solution in a pre-filled pen
Administration: Subcutaneous injection
Usual starting dose: 2.5 mg once weekly
Prescription status in Switzerland: Prescription-only medicine
Marketing authorisation holder: Eli Lilly (Suisse) SA (Swissmedic)
Always check the current Swiss patient information and professional information for the complete and most up-to-date product details.
Mounjaro 2.5 mg – Switzerland: Frequently Asked Questions
Is Mounjaro 2.5 mg available in Switzerland?
Mounjaro 2.5 mg is an authorised strength of Mounjaro in Switzerland. It is a prescription medicine and should be supplied and used according to Swiss pharmaceutical requirements. (Swissmedic)
Is 2.5 mg the starting dose?
Yes. Swissmedic identifies 2.5 mg once weekly as the usual initial dose. Subsequent dose changes should be determined by the treating healthcare professional. (Swissmedic)
Is Mounjaro used for weight loss in Switzerland?
Swissmedic authorised Mounjaro for chronic weight management in eligible adults in combination with a calorie-reduced diet and increased physical activity. Eligibility depends on BMI and relevant weight-related health conditions. (Swissmedic)
Is Mounjaro a prescription medicine?
Yes. Mounjaro is classified as a prescription-only medicine in Switzerland. (Swissmedic)
What is the active ingredient?
The active ingredient is tirzepatide. (Swissmedic)
Where can I find official Swiss information?
Swissmedic provides authorised medicinal-product information through its official information platforms. Patients should refer to the current patient leaflet and speak with a healthcare professional for personalised advice. (Swissmedic)
Important Notice
This page is intended for general product information only and does not constitute medical advice, diagnosis or a recommendation to start treatment. Mounjaro should only be used following an appropriate prescription and according to the current Swiss patient information and instructions from a qualified healthcare professional.
For the most current information regarding Mounjaro KwikPen 2.5 mg, tirzepatide, dosage, contraindications, interactions, side effects and correct pen use in Switzerland, consult your doctor, pharmacist or the official Swissmedic medicinal-product information.
